Progression-Free Survival: Meaningful or Simply Measurable?BOOTH, Christopher M; EISENHAUER, Elizabeth A.Journal of clinical oncology. 2012, Vol 30, Num 10, pp 1030-1033, issn 0732-183X, 4 p.Article

Proposal for the use of progression-free survival in unblinded randomized trialsFREIDLIN, Boris; KORN, Edward L; HUNSBERGER, Sally et al.Journal of clinical oncology. 2007, Vol 25, Num 15, pp 2122-2126, issn 0732-183X, 5 p.Article

Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysisAMIT, O; MANNINO, F; STONE, A. M et al.European journal of cancer (1990). 2011, Vol 47, Num 12, pp 1772-1778, issn 0959-8049, 7 p.Article

Clinical benefit of early phase clinical trial participation for advanced sarcoma patientsJONES, Robin L; OLMOS, David; THWAY, Khin et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 2, pp 423-429, issn 0344-5704, 7 p.Article

The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free SurvivalSULLIVAN, Daniel Carl; SCHWARTZ, Lawrence H; BINSHENG ZHAO et al.Clinical cancer research (Print). 2013, Vol 19, Num 10, pp 2621-2628, issn 1078-0432, 8 p.Article

Comparison of Power Between Randomized Discontinuation Design and Upfront Randomization Design on Progression-Free SurvivalPINGFU FU; DOWLATI, Afshin; SCHLUCHTER, Mark et al.Journal of clinical oncology. 2009, Vol 27, Num 25, pp 4135-4141, issn 0732-183X, 7 p.Article

Issues in Using Progression-Free Survival When Evaluating Oncology ProductsFLEMING, Thomas R; ROTHMANN, Mark D; LU, Hong Laura et al.Journal of clinical oncology. 2009, Vol 27, Num 17, pp 2874-2880, issn 0732-183X, 7 p.Article

Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphomaKUMAGAI, Shogo; TASHIMA, Masaharu; ARIMA, Nobuyoshi et al.International journal of hematology. 2014, Vol 99, Num 6, pp 737-742, issn 0925-5710, 6 p.Article

Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial designYONG WHA MOON; SUN YOUNG RHA; JEUNG, Hei-Cheul et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 4, pp 797-805, issn 0344-5704, 9 p.Article

Postprogression survival for first-line chemotherapy in patients with advanced gastric cancerKAWAKAMI, Hisato; OKAMOTO, Isamu; HAYASHI, Hidetoshi et al.European journal of cancer (1990). 2013, Vol 49, Num 14, pp 3003-3009, issn 0959-8049, 7 p.Article

Statistical methodology for personalized medicine: New developments at EORTC Headquarters since the turn of the 21^st CenturyCOLLETTE, L; BOGAERTS, J; LITIERE, S et al.European journal of cancer. Supplement (1990). 2012, Vol 10, Num 1, pp 13-19, issn 1359-6349, 7 p.Article

Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patientsREBMANN, Vera; SCHÜTT, Philipp; BRANDHORST, Dieter et al.Clinical immunology (Orlando, Fla. Print). 2007, Vol 123, Num 1, pp 114-120, issn 1521-6616, 7 p.Article

Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studiesLINJUAN XU; JING CAI; QIANG YANG et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 8, pp 1257-1277, issn 0171-5216, 21 p.Article

Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpointKOVALCHIK, Stephanie; MIETLOWSKI, William.Contemporary clinical trials. 2011, Vol 32, Num 1, pp 99-107, issn 1551-7144, 9 p.Article

A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: A combined analysis of 10 EORTC trialsFRANCART, J; VAES, E; HENRARD, S et al.European journal of cancer (1990). 2009, Vol 45, Num 13, pp 2304-2311, issn 0959-8049, 8 p.Article

Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practiceROBINSON, Andrew G; BOOTH, Christopher M; EISENHAUER, Elizabeth A et al.European journal of cancer (1990). 2014, Vol 50, Num 13, pp 2303-2308, issn 0959-8049, 6 p.Article

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancerWALLWIENER, Markus; HARTKOPF, Andreas Daniel; AKTAS, Bahriye et al.Breast cancer research and treatment. 2013, Vol 137, Num 2, pp 503-510, issn 0167-6806, 8 p.Article

Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumorsKIRKWOOD, John M; TARHINI, Ahmad; SPARANO, Joseph A et al.Cancer treatment reviews. 2013, Vol 39, Num 1, pp 27-43, issn 0305-7372, 17 p.Article

Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapySHITARA, Kohei; MATSUO, Keitaro; MURO, Kei et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 8, pp 1383-1389, issn 0171-5216, 7 p.Article

Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials : Important Design Element or Unnecessary Expense?DODD, Lori E; KORN, Edward L; FREIDLIN, Boris et al.Journal of clinical oncology. 2008, Vol 26, Num 22, pp 3791-3796, issn 0732-183X, 6 p.Article

Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical TrialsSRIDHARA, Rajeshwari; MANDREKAR, Sumithra J; DODD, Lori E et al.Clinical cancer research (Print). 2013, Vol 19, Num 10, pp 2613-2620, issn 1078-0432, 8 p.Article

Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid TumorsKORN, Ronald L; CROWLEY, John J.Clinical cancer research (Print). 2013, Vol 19, Num 10, pp 2607-2612, issn 1078-0432, 6 p.Article

Residual Serum Monoclonal Protein Predicts Progression-Free Survival in Patients With Previously Untreated Multiple MyelomaSCHAEFER, Eric W; KUMAR, Shaji; DISPENZIERI, Angela et al.Cancer. 2010, Vol 116, Num 3, pp 640-646, issn 0008-543X, 7 p.Article

Local Progression After Radiofrequency Ablation for Pulmonary MetastasesVON MEYENFELDT, Erik M; PREVOO, Warner; PEYROT, David et al.Cancer. 2011, Vol 117, Num 16, pp 3781-3787, issn 0008-543X, 7 p.Article

Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trialsTANG, P. A; POND, G. R; CHEN, E. X et al.Annals of oncology. 2010, Vol 21, Num 1, pp 19-26, issn 0923-7534, 8 p.Article